Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma

Next Previous
Search
Trial Profile

A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bendamustine (Primary) ; Bortezomib (Primary) ; Bortezomib (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary)
  • Indications B-cell lymphoma; Diffuse lymphoma; Follicular lymphoma; Lymphoma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Acronyms BIONIC

    • Most Recent Events

    • 12 Jan 2023 Status changed from active, no longer recruiting to completed.
    • 02 Dec 2020 According to a Rutgers Cancer Institute media release, data from this study will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, being held virtually from December 5-8.
    • 27 Oct 2020 Planned End Date changed from 1 Apr 2023 to 8 May 2030.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top